195 related articles for article (PubMed ID: 36795604)
1. A Systematic Review of Drug-Carrying Nanosystems Used in the Treatment of Leishmaniasis.
Registre C; Soares RDOA; Rubio KTS; Santos ODH; Carneiro SP
ACS Infect Dis; 2023 Mar; 9(3):423-449. PubMed ID: 36795604
[TBL] [Abstract][Full Text] [Related]
2. Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Ortega V; Giorgio S; de Paula E
J Liposome Res; 2017 Sep; 27(3):234-248. PubMed ID: 28874072
[TBL] [Abstract][Full Text] [Related]
3. Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs.
Roseboom IC; Rosing H; Beijnen JH; Dorlo TPC
Biomed Chromatogr; 2023 Jul; 37(7):e5519. PubMed ID: 36208186
[TBL] [Abstract][Full Text] [Related]
4. Paromomycin in the treatment of leishmaniasis.
Sundar S; Chakravarty J
Expert Opin Investig Drugs; 2008 May; 17(5):787-94. PubMed ID: 18447603
[TBL] [Abstract][Full Text] [Related]
5. Leishmaniasis: current treatment and prospects for new drugs and vaccines.
Kedzierski L; Sakthianandeswaren A; Curtis JM; Andrews PC; Junk PC; Kedzierska K
Curr Med Chem; 2009; 16(5):599-614. PubMed ID: 19199925
[TBL] [Abstract][Full Text] [Related]
6. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
7. Leishmaniasis: current status of available drugs and new potential drug targets.
Singh N; Kumar M; Singh RK
Asian Pac J Trop Med; 2012 Jun; 5(6):485-97. PubMed ID: 22575984
[TBL] [Abstract][Full Text] [Related]
8. Challenges and new discoveries in the treatment of leishmaniasis.
Singh S; Sivakumar R
J Infect Chemother; 2004 Dec; 10(6):307-15. PubMed ID: 15614453
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of Ir-(COT)-pentamidine alizarin red and pentamidine, amphotericin B, and paromomycin on Leishmania donovani.
Mbongo N; Loiseau PM; Craciunescu DG; Robert-Gero M
Acta Trop; 1998 Jun; 70(2):239-45. PubMed ID: 9698271
[No Abstract] [Full Text] [Related]
10. Promising therapeutic targets for antileishmanial drugs.
Werbovetz KA
Expert Opin Ther Targets; 2002 Aug; 6(4):407-22. PubMed ID: 12223057
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnological Strategies for Treatment of Leishmaniasis--A Review.
de Almeida L; Terumi Fujimura A; Del Cistia ML; Fonseca-Santos B; Braga Imamura K; Michels PAM; Chorilli M; Graminha MAS
J Biomed Nanotechnol; 2017 Feb; 13(2):117-33. PubMed ID: 29376626
[TBL] [Abstract][Full Text] [Related]
12. The treatment of visceral leishmaniasis: safety and efficacy.
Jha RK; Sah AK; Shah DK; Sah P
JNMA J Nepal Med Assoc; 2013; 52(192):645-51. PubMed ID: 25327244
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance in Indian visceral leishmaniasis.
Sundar S
Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
[TBL] [Abstract][Full Text] [Related]
14. Marine Algae as Source of Novel Antileishmanial Drugs: A Review.
Tchokouaha Yamthe LR; Appiah-Opong R; Tsouh Fokou PV; Tsabang N; Fekam Boyom F; Nyarko AK; Wilson MD
Mar Drugs; 2017 Oct; 15(11):. PubMed ID: 29109372
[TBL] [Abstract][Full Text] [Related]
15. Visceral leishmaniasis - current therapeutic modalities.
Sundar S; Chatterjee M
Indian J Med Res; 2006 Mar; 123(3):345-52. PubMed ID: 16778315
[TBL] [Abstract][Full Text] [Related]
16. Application of nanotechnology in treatment of leishmaniasis: A Review.
Akbari M; Oryan A; Hatam G
Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833
[TBL] [Abstract][Full Text] [Related]
17. Comparison of
Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M
Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583
[TBL] [Abstract][Full Text] [Related]
18. Current scenario of drug development for leishmaniasis.
Croft SL; Seifert K; Yardley V
Indian J Med Res; 2006 Mar; 123(3):399-410. PubMed ID: 16778319
[TBL] [Abstract][Full Text] [Related]
19. Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei.
Collett CF; Kitson C; Baker N; Steele-Stallard HB; Santrot MV; Hutchinson S; Horn D; Alsford S
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160283
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of Curcumin and its Derivatives as Valuable Sources of Antileishmanial Agents.
Albalawi AE; Alanazi AD; Sharifi I; Ezzatkhah F
Acta Parasitol; 2021 Sep; 66(3):797-811. PubMed ID: 33770343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
